

**Alfacalcidol****Section**

Medicines for endocrine disorders

- Oral > Liquid: 2 µg per mL
- Oral > Solid > capsule: 0.25 µg; 1 µg

**Indications**

Chronic kidney disease, stage unspecified

Disorders of vitamin D metabolism or transport

**Beinaglutide****Section**

Hypoglycaemic agents

**Indications**Therapeutic equivalent to [semaglutide](#) for

Obesity

**Bromocriptine****Section**

Medicines for disorders of the pituitary hormone system

**Indications**Therapeutic equivalent to [cabergoline](#) for

Other specified benign neoplasm of endocrine glands

**Cabergoline****Section**

Medicines for disorders of the pituitary hormone system

- Oral > Solid > tablet: 0.5 mg; 1 mg

**Indications**

Other specified benign neoplasm of endocrine glands

**Calcitriol****Section**

Medicines for endocrine disorders

- Oral > Solid > capsule: 0.25 µg; 0.5 µg

**Indications**

Chronic kidney disease, stage unspecified

Disorders of vitamin D metabolism or transport

## Canagliflozin

### Section

Hypoglycaemic agents

### Indications

Therapeutic equivalent to empagliflozin for

Type 2 diabetes mellitus

## Carbimazole

### Section

Thyroid hormones and antithyroid medicines

### Indications

Therapeutic equivalent to methimazole for

Thyrotoxicosis

## Dapagliflozin

### Section

Hypoglycaemic agents

### Indications

Therapeutic equivalent to empagliflozin for

Type 2 diabetes mellitus

## Diazoxide

### Section

Medicines for hypoglycaemia

- Oral > Liquid: 50 mg per mL
- Oral > Solid: 50 mg

### Indications

Persistent hyperinsulinaemic hypoglycaemia of infancy

## Dulaglutide

### Section

Hypoglycaemic agents

### Indications

Therapeutic equivalent to semaglutide for

Obesity

Therapeutic equivalent to semaglutide for

Type 2 diabetes mellitus

## Empagliflozin

### Section

Hypoglycaemic agents

- Oral > Solid: 10 mg; 25 mg

### Indications

Type 2 diabetes mellitus

## Estradiol

### Section

#### Estrogens

- Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg

### Indications

Hypopituitarism

Gonadotropin deficiency

Turner syndrome

## Exenatide

### Section

#### Hypoglycaemic agents

### Indications

Therapeutic equivalent to [semaglutide](#) for

Obesity

## Fludrocortisone

### Section

#### Adrenal hormones and synthetic substitutes

- Oral > Liquid: 100 µg per mL
- Oral > Solid > tablet: 100 µg (acetate)

### Indications

Adrenocortical insufficiency

## Glibenclamide

### Section

#### Hypoglycaemic agents

- Oral > Solid: 5 mg; 2.5 mg

### Indications

Type 2 diabetes mellitus

## Gliclazide

### Section

#### Hypoglycaemic agents

- Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release

### Indications

Type 2 diabetes mellitus

## Glucagon

### Section

#### Medicines for hypoglycaemia

- Parenteral > General injections > unspecified: 1 mg per mL as powder and diluent

### Indications

Hypoglycaemia in the context of diabetes

## Hydrocortisone

### Section

#### Adrenal hormones and synthetic substitutes

- Oral > Solid > tablet: 5 mg; 10 mg; 20 mg
- Oral > Solid > granules: 0.5 mg in capsule; 1 mg in capsule; 2 mg in capsule; 5 mg in capsule

### Indications

Adrenocortical insufficiency

## Insulin (analogue, long-acting)

### Section

#### Insulins

- Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution; 100 IU per mL in 10 mL vial solution

### Indications

Type 2 diabetes mellitus

Type 1 diabetes mellitus

## Insulin (analogue, rapid-acting)

### Section

#### Insulins

- Parenteral > General injections > SC: 100 IU per 1 mL in 10 mL vial; 100 IU per 1 mL in 3 mL cartridge; 100 IU per 1 mL in 3 mL pre-filled pen

### Indications

Type 1 diabetes mellitus

Type 2 diabetes mellitus

## Insulin (human, intermediate-acting)

### Section

#### Insulins

- Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin

### Indications

Type 2 diabetes mellitus

Type 1 diabetes mellitus

## Insulin (human, short-acting)

### Section

#### Insulins

- Parenteral > General injections > SC: 40 IU per mL in 10 mL vial solution; 100 IU per mL in 10 mL vial solution; 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution

### Indications

Type 2 diabetes mellitus

Type 1 diabetes mellitus

## Insulin analogues

### Section

#### Insulins

- Not specified

### Indications

Type 2 diabetes mellitus

Type 1 diabetes mellitus

## Insulin aspart

### Section

#### Insulins

- Parenteral > General injections > SC: 100 IU per mL in 110 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
- Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

### Indications

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 2 diabetes mellitus

## Insulin degludec

### Section

#### Insulins

- Parenteral > General injections > SC: 100 units per mL

### Indications

Therapeutic equivalent to [insulin glargine](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for

Type 2 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for

Type 1 diabetes mellitus

## Insulin detemir

### Section

#### Insulins

### Indications

Therapeutic equivalent to [insulin glargine](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for

Type 2 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for

Type 1 diabetes mellitus

## Insulin glargine

### Section

#### Insulins

- Parenteral > General injections > SC: 100 units per mL

### Indications

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for

Type 2 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for

Type 1 diabetes mellitus

## Insulin glulisine

### Section

#### Insulins

- Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

### Indications

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 2 diabetes mellitus

## Insulin lispro

### Section

#### Insulins

- Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

### Indications

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 2 diabetes mellitus

## Iodine + potassium iodide (Lugol's solution)

### Section

#### Thyroid hormones and antithyroid medicines

- Oral > Liquid: 5% w/v + 10% w/v (aqueous)

### Indications

Thyrotoxicosis

## Ketoconazole

### Section

#### Medicines for endocrine disorders

- Oral > Solid > tablet: 200 mg

### Indications

Cushing syndrome

## Levothyroxine

### Section

#### Thyroid hormones and antithyroid medicines

- Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)

### Indications

Hypothyroidism

## Liraglutide

### Section

#### Medicines for endocrine disorders

- Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen

#### Hypoglycaemic agents

### Indications

Obesity

Therapeutic equivalent to [semaglutide](#) for

Obesity

Therapeutic equivalent to [semaglutide](#) for

Type 2 diabetes mellitus

## Medroxyprogesterone acetate

### Section

#### Progestogens

- Oral > Solid: 5 mg

### Indications

Excessive menstruation with irregular cycle

## Metformin

### Section

#### Hypoglycaemic agents

- Oral > Solid: 500 mg (hydrochloride)

### Indications

Type 2 diabetes mellitus

## Methimazole

### Section

#### Thyroid hormones and antithyroid medicines

- Oral > Solid > tablet: 5 mg; 10 mg

### Indications

Thyrotoxicosis

## Norethisterone

### Section

#### Progestogens

- Oral > Solid: 5 mg

### Indications

Excessive menstruation with irregular cycle

Therapeutic equivalent to medroxyprogesterone acetate for

Excessive menstruation with irregular cycle

## Octreotide

### Section

#### Medicines for disorders of the pituitary hormone system

- Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent
- Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)

### Indications

Acromegaly or pituitary gigantism

## Phosphorus

### Section

#### Medicines for endocrine disorders

- Oral > Other: 500 mg in sachet (elemental phosphorus) granules
- Oral > Solid > tablet: 250 mg (elemental phosphorus); 500 mg (elemental phosphorus); 500 mg (elemental phosphorus) (effervescent)

### Indications

Hypophosphataemic rickets

## Potassium iodide

### Section

#### Thyroid hormones and antithyroid medicines

- Oral > Solid > tablet: 65 mg (scored)

### Indications

Thyrotoxicosis

## Prednisolone

### Section

#### Adrenal hormones and synthetic substitutes

- Oral > Solid > tablet: 1 mg

### Indications

Adrenocortical insufficiency

## Prednisone

### Section

#### Adrenal hormones and synthetic substitutes

- Oral > Solid > tablet: 1 mg

### Indications

Therapeutic equivalent to prednisolone for

Adrenocortical insufficiency

## Propylthiouracil

### Section

#### Thyroid hormones and antithyroid medicines

- Oral > Solid: 50 mg

### Indications

Thyrotoxicosis

## Semaglutide

### Section

#### Hypoglycaemic agents

- Parenteral > General injections > SC: 0.25 mg in pre-filled pen injection solution; 0.5 mg in pre-filled pen injection solution; 1 mg in pre-filled pen injection solution; 2 mg in pre-filled pen injection solution; 4 mg in pre-filled pen injection solution
- Oral > Solid > tablet: 3 mg
- Parenteral > General injections > SC: 0.68 mg per mL; 1.34 mg per mL; 2.68 mg per mL

### Indications

Obesity

Type 2 diabetes mellitus

## Simvastatin

### Section

#### Medicines for endocrine disorders

- Oral > Solid: 20 mg

### Indications

Polycystic ovary syndrome

## Somatropin

### Section

#### Medicines for endocrine disorders

- Parenteral > General injections > SC: 5 mg in cartridge powder for injection; 5 mg per mL in 2 mL cartridge

### Indications

Hypoglycaemia without associated diabetes

## Testosterone

### Section

#### Androgens

- Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)

### Indications

Testicular dysfunction or testosterone-related disorders

## Tirzepatide

### Section

#### Hypoglycaemic agents

### Indications

Therapeutic equivalent to [semaglutide](#) for

Obesity

Therapeutic equivalent to [semaglutide](#) for

Type 2 diabetes mellitus

## Tolbutamide

### Section

#### Hypoglycaemic agents

- Oral > Solid: 500 mg

### Indications

Type 2 diabetes mellitus

## Zoledronic acid

### Section

#### Medicines for endocrine disorders

- Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

### Indications

Osteogenesis imperfecta